Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
NxStage Medical, Inc.
(Exact name of registrant as specified in its charter)
|
| | |
Delaware | 000-51567 | 04-3454702 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| | |
350 Merrimack Street, Lawrence, MA | | 01843 |
(Address of Principal Executive Offices) | | (Zip Code) |
Matthew W. Towse
Chief Financial Officer
(978) 687-4700
(Name and telephone number, including area code, of the person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
þ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to
December 31, 2017.
Section 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
NxStage Medical, Inc.'s Conflict Minerals Report for the reporting period from January 1, 2017 to December 31, 2017 is filed herewith as Exhibit 1.01 and is publicly available at ir.nxstage.com.
Item 1.02 Exhibit
The exhibit listed in Item 2.01 is filed as part of this report.
Section 2 - Exhibits
Item 2.01 Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
NxSTAGE MEDICAL, INC.
By: /s/ Matthew W. Towse Date: May 31, 2018
Matthew W. Towse
Chief Financial Officer